SEC Form 4 · accession 0001700659-26-000014
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Pakola
Officer — Chief Medical Officer
Period of report
Jul 2, 2026
Accepted (ET)
Jul 6, 2026 · 4:51 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2026 | M | 2,161 | $7.86 | A | 215,170 | D | |
| Common Stock | Jul 2, 2026 | S | 2,161 | $13.64 | D | 213,009 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $7.86 | Jul 2, 2026 | M | 2,161 | D | — | Jan 2, 2035 | Common Stock | 2,161 | 64,812 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.